Overexpression of CRLF2 is present in up to 15% of high risk BCP-ALL patients [5] and 50% of both Down Syndrome–associated BCP-ALL and Ph-like BCP-ALL patients [8-10]. Here, CRLF2 is linked to acute lymphoblastic leukemia.